Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions

• Status: Unknown status
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Using transcriptomics and proteomics to gain insights in the development of psoriasiform skin lesions under anti-tumor necrosis factor (TNF) therapy, and predicting response to ustekinumab.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitaire Ziekenhuizen Leuven
• Treatments: Ustekinumab; Vedolizumab

Criteria

Inclusion Criteria:

• Patients with CD or UC, who develop psoriasiform skin lesions (including psoriasiform eczema, psoriasis guttata, psoriasis inversa and pustulosis) under therapy with anti-TNF and refractory to at least 12 weeks of topical therapy.

• Written informed consent must be obtained and documented.

Exclusion Criteria:

• IBD patients not treated with anti-TNF therapy

• IBD patients with skin lesions under anti-TNF not refractory to topical therapy

• Patients who previously received anti-interleukin 12/23 (IL12/23) or anti-interleukin 23 therapy

• Patients with history of psoriasis prior to initiation of anti-TNF therapy